%0 Journal Article
%A Garcia-Gutierrez, Valentin
%A Luna, Alejandro
%A Alonso-Dominguez, Juan M
%A Estrada, Natalia
%A Boque, Concepcion
%A Xicoy, Blanca
%A Giraldo, Pilar
%A Angona, Anna
%A Alvarez-Larran, Alberto
%A Sanchez-Guijo, Fermin
%A Ramirez, Maria Jose
%A Mora, Elvira
%A Velez, Patricia
%A Rosell, Ana
%A Colorado-Araujo, Mercedes
%A Cuevas, Beatriz
%A Sagües, Miguel
%A Cortes, Montserrat
%A Perez-Encinas, Manuel 
%A Casado Montero, Luis Felipe
%A Moreno-Vega, Melania
%A Serrano, Luis
%A Gomez, Valle
%A Garcia-Hernandez, Carmen
%A Lakhwani, Sunil
%A Paz-Coll, Antonio
%A de-Paz, Raquel
%A Suarez-Varela, Sara
%A Fernandez-Ruiz, Andres
%A Perez-Lopez, Raul
%A Ortiz-Fernandez, Almudena
%A Jimenez-Velasco, Antonio
%A Steegmann-Olmedillas, Juan Luis
%A Hernandez-Boluda, Juan Carlos
%T Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
%D 2021
%U http://hdl.handle.net/10668/17137
%X Despite the excellent overall survival (OS) of chronic myeloid leukemia (CML) patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) due to resistance or intolerance. Intolerant patients are usually managed successfully with alternative second-generation tyrosine-kinase inhibitors (2GTKIs). However, more than half of the patients will eventually discontinue second-line treatment due to loss of response or toxicity. Ponatinib is an effective drug in the setting of resistance to 2GTKIs, however with life-threatening side effects and varying responses.
%K Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
%K Protein Kinase Inhibitors
%K Pyrazoles
%K Treatment Outcome
%K Young Adult
%~